Recently, a collaborative effort among research centers in the United States and Europe resulted in the development of ...

The PSMA-targeting ligand 177 Lu-PSMA-617 was prepared in compliance with good manufacturing practices. Radio–high-performance liquid chromatography as the primary method of quality control was ...

We took a novel approach to testing between the competing models of Aβ accumulation: we used the whole-cortex Aβ profile derived from the longitudinal study of Jack et al. (in which the patients did ...

The recently released Biograph mMR is the first commercially available integrated whole-body PET/MR scanner. There are considerable advantages to integrating both modalities in a single scanner that ...

Journal of Nuclear Medicine April 2025, jnumed.124.269132; DOI: https://doi.org/10.2967/jnumed.124.269132 ...

Theranostic strategies involve select radionuclides that allow diagnostic imaging and tailored radionuclide therapy in the same patient. An example of a Food and Drug Administration–approved ...

RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...

There is a significantly growing interest in diagnostic and therapeutic radiopharmaceuticals, and it is foreseeable that an unprecedented number of patients will need to be treated with new nuclear ...

Congenital hyperinsulinism is characterized by persistent hypoglycemia due to inappropriate excess secretion of insulin resulting in hyperinsulinemic hypoglycemia. The clinical course varies from mild ...

The internal dosimetry schema of the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine has provided a broad framework for assessment of the absorbed dose to whole ...

Radiopharmaceutical therapy (RPT) of patients with differentiated metastatic thyroid cancer has been standard treatment for more than 80 y. A high and uniform expression of the NaI symporter in ...

Nectin cell adhesion molecule 4 (Nectin-4) is an emerging biomarker for cancer diagnosis and therapy. We developed a Nectin-4–targeted 68Ga-DOTA-Sar10-Nectin-4 (68Ga-FZ-NR-1) PET/CT radiotracer for ...